The content on this site is intended for healthcare professionals only
Prof Laura Dawson speaks to ecancer about her randomised phase III study of sorafenib vs. SBRT followed by sorafenib in hepatocellular carcinoma.
The study investigated if SBRT followed by sorafenib (SBRT/S) improves overall survival (OS), progression-free survival (PFS) and quality of life (QOL) vs. sorafenib alone (S), in patients with HCC.
Compared to sorafenib alone, SBRT improved OS & PFS in patients with HCC, with no observed increase in adverse events, and a strong suggestion for QOL benefit at 6 months. Prof Dawson concludes by talking about the clinical impact of these results.
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer
Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer
Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepatocellular carcinoma
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
